Q&A: State of Prostate Cancer Care
Each year, about 220,000 men in the United States are diagnosed with prostate cancer, which remains the second-leading cause of cancer-related death among men. Over the past decade, new technologies and treatment approaches have begun to change how urologists and oncologists diagnose and treat the disease.
Christopher Anderson, MD, MPH, urologic surgeon and director of the Division of Urologic Oncology and Izak Faiena, MD, MSCR, urologic oncologist at NewYork-Presbyterian/Columbia University Medical Center, discuss how these advances are improving the diagnosis, prognosis, and treatment of prostate cancer at Columbia.
How has treatment for prostate cancer shifted over the last decade?
Prostate cancer is becoming increasingly personalized. The more we learn about prostate cancer, the more we can tailor treatment based on the tumor biology and patient’s overall health and treatment goals. More advanced imaging, targeted biopsies, and novel treatments have added even more to the armamentarium of what we can do. There’s always a balance of providing the most effective cancer treatment with preserving important aspects of quality of life, such as sexual, urinary, and bowel function, and addressing treatment at a more personal level has been one of the biggest shifts in the past 10 years.
There’s also been a huge change in how we think about prostate cancer, beginning with the question of who benefits from an early diagnosis through screening. In addition, since localized prostate cancer is often a slow-growing disease, we work hard to identify which men could be harmed by their cancer if left untreated and which men are not likely to be harmed from indolent disease. In many cases, we can now comfortably tell a patient who, 10 years ago, would have received aggressive treatment that their cancer is very unlikely to harm them and can avoid aggressive treatments.
How has focal therapy expanded the potential for treating prostate cancer? Which patients could benefit from this?
Standard treatments for more aggressive prostate cancers generally include either removing the entire prostate or delivering radiation to the entire prostate. The main idea of focal therapy is that by only treating a portion of the prostate using minimally invasive technologies, you can reduce the risk of side effects (sparing healthy prostate tissue, urinary function, and sexual potency).
With our new imaging modalities, targeted biopsies, genomic testing, and advancements in localizing prostate cancer with advanced imaging , we can better identify eligible patients and deliver more successful focal therapy treatments. Going forward, we aim to understand which patients are most likely to benefit from focal therapy, specifically well-selected patients with grade 2 and grade 3 prostate cancer. And as a leader in focal therapy, Columbia is working to advance the biomarker field through cutting-edge research on novel biomarkers to improve patient selection and monitoring.
How have surgical operations for prostate cancer evolved?
From a surgical standpoint, we have a much better understanding now of who is likely to recover their function to the way it was before their surgery. The two major side-effects from prostate cancer surgery are a change in urinary function, specifically leakage of urine, and a change in sexual function, including erectile dysfunction. The better you can match patients who are likely to preserve or regain that function after surgery combined with some newer surgical techniques, the better our patients will recover after surgery.
What are some new advancements you have been using in the OR?
We use the da Vinci robot to perform radical prostatectomy. As we have learned more about which structures around the prostate are critical to preserve or reconstruct during prostatectomy, we allow men to have excellent functional outcomes postoperatively. Urinary leakage is generally mild and temporary, and most men with good erectile function before surgery can still get erections after surgery if these critical structures can be safely preserved. One new advancement in robotic tech is the da Vinci SP single port robot which, instead of making five small incisions on the skin, allows for robotic surgery through just one small incision. This technique can allow for complex minimally invasive surgery in patients where a multi-port technique would not be possible.
How does Columbia stand out when it comes to treating prostate cancer in the OR?
We live and practice in a very competitive healthcare environment. There are more urologists in New York than anywhere else in the country. Many people come to New York specifically to get their care, oftentimes specifically for prostate cancer care.
No two men with prostate cancer are the same, and we work hard to understand each patient’s goals, needs, concerns, and options. We listen to our patients and match the best treatment to each individual patient within our multi-disciplinary team.
Numerous studies show that surgeon experience is paramount to the success of our treatments. Our patients seek us out not only for our patient-centered approach to prostate cancer care, but also our experience. At Columbia, we have performed thousands of robotic prostatectomies and our surgical outcomes rival those of other high-volume centers.
Members of the Columbia Genitourinary Cancer Care Team from left to right: Christopher Anderson, MD, Catherine Spina, MD, PhD, Mark Stein, MD, and Alexander Wei, MD.
What research is catching your eye right now?
Catherine Spina, MD, PhD, one of our leading radiation genitourinary oncologists, is leading research on how radiation can be combined with new treatments to improve its effectiveness. Her work focuses on the ability of radiation to shape the immune response, with the goal of developing more effective combinations of radiation and immunotherapy.
Mark Stein, MD, the chief of genitourinary medical oncology at Columbia, and his colleagues are also advancing new approaches to systemic therapy through a range of clinical trials, including studies of novel immunotherapies for prostate cancer. Current trials at Columbia are investigating approaches such as T-cell–redirecting therapies, CAR T-cell therapy, and combinations of immunotherapy with other targeted treatments.
Looking ahead, where do you see the field going in the next decade?
Our ability to prognosticate prostate cancer will continue to improve. We have new tests performed on prostate cancer tissue, including a new AI-based biomarker, which can provide more information compared to what we see under the microscope. As more research is done on this and other algorithms, we hope to better identify which patients need more treatment and which may need less.
There are also some interesting medications that are being studied as a means to improve the cure rates for both surgery and radiation. Typically, these drugs are first studied in patients with advanced disease to determine whether they are effective. If they show benefit, they may then be studied at earlier stages of the disease, eventually reaching patients with localized prostate cancer.
A recent trial published this year in the New England Journal of Medicine, for example, suggested that the addition of potent androgen-deprivation therapy (ADT) for men with aggressive prostate cancer can improve cancer control after surgery.
At the same time, new technologies can help us more precisely identify and target the disease during treatment. These technologies may allow us to better identify and target the cancer and ultimately improve treatment success. That’s what makes this field so exciting -- there’s a lot of research, interest, and many stakeholders working to improve care for patients with prostate cancer.